Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | ACE | P12821 | 4/20 | 0.36 |
| ▸ | REN | P00797 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL499847 | 0.80 | MEN1 (0.44) | L3MBTL1LTA4HHTTOPRD1ACE | |
| SCHEMBL7763371 | 0.78 | POLB (0.52) | L3MBTL1LTA4HOPRD1ACEALDH1A1 | |
| SCHEMBL23802767 | 0.78 | MDM2 (0.36) | SLC6A9POLB | |
| SCHEMBL23802866 | 0.78 | MDM2 (0.36) | SLC6A9POLB | |
| SCHEMBL20585525 | 0.77 | S1PR1 (0.43) | L3MBTL1LTA4HHTTOPRD1ACE | |
| SCHEMBL15925112 | 0.76 | LTA4H (0.39) | L3MBTL1LTA4HHTTOPRD1ACE | |
| SCHEMBL10453847 | 0.76 | SLC6A9 (0.41) | L3MBTL1HTTSLC6A9ALDH1A1CHRM3 | |
| SCHEMBL12621119 | 0.76 | L3MBTL1 (0.49) | L3MBTL1HTTSLC6A9ALDH1A1RAB9A | |
| SCHEMBL439589 | 0.76 | L3MBTL1 (0.49) | L3MBTL1HTTSLC6A9ALDH1A1RAB9A | |
| SCHEMBL12621117 | 0.76 | L3MBTL1 (0.49) | L3MBTL1HTTSLC6A9ALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349857-B2 | Quinazoline derivatives having tyrosine kinase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2013-01-08 | — | — | US | disclosed |
| US-8202879-B2 | Quinazoline derivatives having tyrosine kinase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2012-06-19 | — | — | US | disclosed |
| US-20090143414-A1 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity | SHIONOGI & CO., LTD. (JP) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143414-A1 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity | ERBB2, EGFR, ABL1 | L3MBTL1 4646/4885LTA4H 4734/4885HTT 2073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.